{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:31:17Z","timestamp":1788993077070,"version":"build-2803163510"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":96,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.prdoa.2026.100440","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T07:57:06Z","timestamp":1775721426000},"page":"100440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Lithium as a disease-modifying therapy for Parkinson\u2019s disease: mechanisms, preclinical evidence, and clinical prospects"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6518-3552","authenticated-orcid":false,"given":"Jackson T.","family":"Boonstra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.prdoa.2026.100440_b0005","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"GBD 2016 Parkinson's Disease Collaborators","year":"2018","journal-title":"The Lancet. Neurology"},{"issue":"3","key":"10.1016\/j.prdoa.2026.100440_b0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25292","article-title":"The current and projected economic burden of Parkinson's disease in the United States","volume":"28","author":"Kowal","year":"2013","journal-title":"Movement Disorders : Official J. Movement Dis. Soc."},{"key":"10.1016\/j.prdoa.2026.100440_b0015","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Disease Primers"},{"issue":"12","key":"10.1016\/j.prdoa.2026.100440_b0020","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Movement Disorders : Official J. Movement Dis. Soc."},{"issue":"3","key":"10.1016\/j.prdoa.2026.100440_b0025","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Movement Disorders : Official J. Movement Dis. Soc."},{"issue":"5","key":"10.1016\/j.prdoa.2026.100440_b0030","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/mds.27360","article-title":"Disease modification in Parkinson's disease: current approaches, challenges, and future considerations","volume":"33","author":"Lang","year":"2018","journal-title":"Movement Disorders : Official J. Movement Dis. Soc."},{"issue":"6","key":"10.1016\/j.prdoa.2026.100440_b0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1021\/cn5000309","article-title":"Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders","volume":"5","author":"Forlenza","year":"2014","journal-title":"ACS Chem. Nerosci."},{"issue":"5","key":"10.1016\/j.prdoa.2026.100440_b0040","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/cdd.2014.179","article-title":"GSK-3\u03b2 dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and \u03b1-synuclein","volume":"22","author":"Credle","year":"2015","journal-title":"Cell Death Differ."},{"issue":"7","key":"10.1016\/j.prdoa.2026.100440_b0045","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1083\/jcb.200504035","article-title":"Lithium induces autophagy by inhibiting inositol monophosphatase","volume":"170","author":"Sarkar","year":"2005","journal-title":"J. Cell Biol."},{"issue":"3","key":"10.1016\/j.prdoa.2026.100440_b0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0014-2999(85)90168-2","article-title":"Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B","volume":"116","author":"Heikkila","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.prdoa.2026.100440_b0055","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fnins.2015.00403","article-title":"Potential application of lithium in Parkinson's and other neurodegenerative diseases","volume":"9","author":"Lazzara","year":"2015","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.prdoa.2026.100440_b0060","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/cells10020230","article-title":"Parkinson's disease: potential actions of lithium by targeting the WNT\/\u03b2-catenin pathway, oxidative stress, inflammation and glutamatergic pathway","volume":"10","author":"Vall\u00e9e","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.prdoa.2026.100440_b0065","doi-asserted-by":"crossref","unstructured":"T. Guttuso Jr., R. Shepherd, D. Sirica, G.E. Wilding, Lithium\u2019s effects on serum neurofilament light in Parkinson\u2019s disease [Preprint], medRxiv, 2025, March 5, https:\/\/doi.org\/10.1101\/2025.03.04.25323314.","DOI":"10.1101\/2025.03.04.25323314"},{"key":"10.1016\/j.prdoa.2026.100440_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114687","article-title":"Relationship between lithium carbonate and the risk of Parkinson-like events in patients with bipolar disorders: a multivariate analysis using the Japanese adverse drug event report database","volume":"314","author":"Uwai","year":"2022","journal-title":"Psychiatry Res."},{"issue":"9817","key":"10.1016\/j.prdoa.2026.100440_b0075","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(11)61516-X","article-title":"Lithium toxicity profile: a systematic review and meta-analysis","volume":"379","author":"McKnight","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.prdoa.2026.100440_b0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-09335-x","article-title":"Lithium deficiency and the onset of Alzheimer's disease","author":"Aron","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.prdoa.2026.100440_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102231","article-title":"Lithium and disease modification: a systematic review and meta-analysis in Alzheimer's and Parkinson's disease","volume":"95","author":"Singulani","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.prdoa.2026.100440_b0090","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ibneur.2023.05.001","article-title":"Lithium's effects on therapeutic targets and MRI biomarkers in Parkinson's disease: a pilot clinical trial","volume":"14","author":"Guttuso","year":"2023","journal-title":"IBRO Neuroscience Reports"},{"issue":"9","key":"10.1016\/j.prdoa.2026.100440_b0095","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1096\/fj.08-120410","article-title":"Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models","volume":"23","author":"Duka","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.prdoa.2026.100440_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1209703","article-title":"The role of glycogen synthase kinase 3 beta in neurodegenerative diseases","volume":"16","author":"Yu","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.prdoa.2026.100440_b0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.phrs.2015.03.010","article-title":"Glycogen synthase kinase-3 beta (GSK-3\u03b2) signaling: Implications for Parkinson's disease","volume":"97","author":"Golpich","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.prdoa.2026.100440_b0110","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/jnr.10318","article-title":"Long-term lithium treatment prevents neurotoxic effects of beta-bungarotoxin in primary cultured neurons","volume":"69","author":"Tseng","year":"2002","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.prdoa.2026.100440_b0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fnmol.2020.00081","article-title":"GSK-3\u03b2 contributes to parkinsonian dopaminergic neuron death: evidence from conditional knockout mice and tideglusib","volume":"13","author":"Li","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"6","key":"10.1016\/j.prdoa.2026.100440_b0120","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1021\/cn500056q","article-title":"Lithium and autophagy","volume":"5","author":"Motoi","year":"2014","journal-title":"ACS Chem. Neurosci."},{"issue":"10","key":"10.1016\/j.prdoa.2026.100440_b0125","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3390\/biom13101435","article-title":"Autophagy in Parkinson's disease","volume":"13","author":"Nechushtai","year":"2023","journal-title":"Biomolecules"},{"issue":"12","key":"10.1016\/j.prdoa.2026.100440_b0130","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.4103\/1673-5374.241473","article-title":"Lithium promotes recovery of neurological function after spinal cord injury by inducing autophagy","volume":"13","author":"Zhang","year":"2018","journal-title":"Neural Regen. Res."},{"issue":"6","key":"10.1016\/j.prdoa.2026.100440_b0135","first-page":"4989","article-title":"Neuroprotective effects of lithium on a chronic MPTP mouse model of Parkinson's disease via regulation of \u03b1\u2011synuclein methylation","volume":"19","author":"Zhao","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.prdoa.2026.100440_b0140","article-title":"Corynoxine protects dopaminergic neurons through inducing autophagy and diminishing neuroinflammation in rotenone-induced animal models of parkinson's disease","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.prdoa.2026.100440_b0145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10616-016-0056-1","article-title":"Lithium chloride promotes neuronal differentiation of rat neural stem cells and enhances neural regeneration in Parkinson's disease model","volume":"69","author":"Qi","year":"2017","journal-title":"Cytotechnology"},{"issue":"s1","key":"10.1016\/j.prdoa.2026.100440_b0150","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.3233\/JPD-223237","article-title":"Microglia in parkinson's disease","volume":"12","author":"Stefanova","year":"2022","journal-title":"J. Parkinsons Dis."},{"issue":"9","key":"10.1016\/j.prdoa.2026.100440_b0155","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.3390\/ijms22094676","article-title":"The contribution of microglia to neuroinflammation in Parkinson's disease","volume":"22","author":"Badanjak","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prdoa.2026.100440_b0160","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbi.2020.09.017","article-title":"Andrographolide suppresses NLRP3 inflammasome activation in microglia through induction of parkin-mediated mitophagy in in-vitro and in-vivo models of Parkinson disease","volume":"91","author":"Ahmed","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.prdoa.2026.100440_b0165","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s11011-023-01189-4","article-title":"Evaluation of the therapeutic potential of cerebrolysin and\/or lithium in the male Wistar rat model of Parkinson\u2019s disease induced by reserpine","volume":"38","author":"Tharwat","year":"2023","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.prdoa.2026.100440_b0170","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","article-title":"Mitochondrial dysfunction and oxidative stress in Parkinson's disease","volume":"106\u2013107","author":"Subramaniam","year":"2013","journal-title":"Prog. Neurobiol."},{"issue":"1","key":"10.1016\/j.prdoa.2026.100440_b0175","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/fcp.12826","article-title":"Is lithium neuroprotective? an updated mechanistic illustrated review","volume":"37","author":"Ghanaatfar","year":"2023","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.prdoa.2026.100440_b0180","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/jnr.22700","article-title":"Lithium protects against oxidative stress-mediated cell death in \u03b1-synuclein-overexpressing in vitro and in vivo models of Parkinson's disease","volume":"89","author":"Kim","year":"2011","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.prdoa.2026.100440_b0185","doi-asserted-by":"crossref","unstructured":"G. Ambrosi, S. Cerri, F. Blandini, A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease, J. Neural Transmission (Vienna, Austria : 1996), 2014, 121(8), 849\u2013859. https:\/\/doi.org\/10.1007\/s00702-013-1149-z.","DOI":"10.1007\/s00702-013-1149-z"},{"issue":"5","key":"10.1016\/j.prdoa.2026.100440_b0190","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1073\/pnas.95.5.2642","article-title":"Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx","volume":"95","author":"Nonaka","year":"1998","journal-title":"PNAS"},{"key":"10.1016\/j.prdoa.2026.100440_b0200","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/NDT.S78226","article-title":"Neuroprotective strategies against calpain-mediated neurodegeneration","volume":"11","author":"Yildiz-Unal","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"11","key":"10.1016\/j.prdoa.2026.100440_b0205","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1021\/acsnano.3c05864","article-title":"Ultrasound-assisted CRISPRi-exosome for epigenetic modification of \u03b1-synuclein gene in a mouse model of parkinson's disease","volume":"18","author":"Kong","year":"2024","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.prdoa.2026.100440_b0210","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1007\/s12035-024-03974-3","article-title":"The Alpha-Synuclein Gene (SNCA) is a genomic target of methyl-CpG binding protein 2 (MeCP2)-implications for Parkinson's disease and rett syndrome","volume":"61","author":"Schmitt","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.prdoa.2026.100440_b0215","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.biopha.2015.08.025","article-title":"MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting \u03b1-synuclein expression in MPTP-induced Parkinson's disease mouse","volume":"74","author":"Wang","year":"2015","journal-title":"Biomed. Pharmacotherapy = Biomed. Pharmacotherapie"},{"key":"10.1016\/j.prdoa.2026.100440_b0220","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.euroneuro.2024.03.010","article-title":"Lithium response in bipolar disorder: epigenome-wide DNA methylation signatures and epigenetic aging","volume":"85","author":"Zafrilla-L\u00f3pez","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.prdoa.2026.100440_b0225","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/pharmrev.120.000007","article-title":"New advances in the pharmacology and toxicology of lithium: a neurobiologically oriented overview","volume":"76","author":"Bortolozzi","year":"2024","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.prdoa.2026.100440_b0230","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/cells10020255","article-title":"Lithium and therapeutic targeting of GSK-3","volume":"10","author":"Snitow","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.prdoa.2026.100440_b0235","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3233\/JAD-220813","article-title":"Low-dose lithium supplementation influences GSK3\u03b2 activity in a brain region specific manner in C57BL6 male mice","volume":"91","author":"Fenech","year":"2023","journal-title":"J. Alzheimer's Dis. : JAD"},{"issue":"3","key":"10.1016\/j.prdoa.2026.100440_b0240","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.neuroscience.2008.06.040","article-title":"Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model","volume":"155","author":"Feng","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.prdoa.2026.100440_b0245","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3233\/JAD-190615","article-title":"Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for neurodegenerative diseases: a systematic review and meta-analysis","volume":"72","author":"Wang","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.prdoa.2026.100440_b0250","article-title":"Neurofilament light chain and \u03b1-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes","volume":"7","author":"Quadalti","year":"2021","journal-title":"npj Parkinson's Dis."},{"issue":"6","key":"10.1016\/j.prdoa.2026.100440_b0255","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.2042-7158.1978.tb13258.x","article-title":"Rat brain and serum lithium concentrations after acute injections of lithium carbonate and orotate","volume":"30","author":"Kling","year":"1978","journal-title":"J. Pharm. Pharmacol."},{"issue":"8","key":"10.1016\/j.prdoa.2026.100440_b0260","doi-asserted-by":"crossref","first-page":"e2262","DOI":"10.1002\/brb3.2262","article-title":"Lithium orotate: a superior option for lithium therapy?","volume":"11","author":"Pacholko","year":"2021","journal-title":"Brain and Behavior"},{"key":"10.1016\/j.prdoa.2026.100440_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.104973","article-title":"A toxicological evaluation of lithium orotate","volume":"124","author":"Murbach","year":"2021","journal-title":"Regul. Toxicol. Pharm."},{"issue":"7","key":"10.1016\/j.prdoa.2026.100440_b0270","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 receptor agonists: a new treatment in parkinson's disease","volume":"25","author":"Kalinderi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prdoa.2026.100440_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109952","article-title":"Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: a revolution in the making?","volume":"253","author":"H\u00f6lscher","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.prdoa.2026.100440_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.109872","article-title":"The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: relevance for bipolar disorder","volume":"99","author":"Chaves Filho","year":"2020","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.prdoa.2026.100440_b0285","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/npp.2015.220","article-title":"The aversive agent lithium chloride suppresses phasic dopamine release through central GLP-1 receptors","volume":"41","author":"Fortin","year":"2016","journal-title":"Neuropsychopharmacology : Official Publication of the Am. College of Neuropsychopharmacology"},{"issue":"16","key":"10.1016\/j.prdoa.2026.100440_b0290","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1073\/pnas.93.16.8455","article-title":"A molecular mechanism for the effect of lithium on development","volume":"93","author":"Klein","year":"1996","journal-title":"PNAS"},{"issue":"14","key":"10.1016\/j.prdoa.2026.100440_b0295","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1073\/pnas.0307921101","article-title":"Lithium antagonizes dopamine-dependent behaviors mediated by an AKT\/glycogen synthase kinase 3 signaling cascade","volume":"101","author":"Beaulieu","year":"2004","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.prdoa.2026.100440_b0300","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3233\/JPD-230363","article-title":"Twelve years of drug prioritization to help accelerate disease modification trials in Parkinson's disease: the international linked clinical trials initiative","volume":"14","author":"Wyse","year":"2024","journal-title":"J. Parkinsons Dis."},{"issue":"2","key":"10.1016\/j.prdoa.2026.100440_b0305","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/mdc3.14264","article-title":"Preferences regarding disclosure of risk for parkinson's disease in a population-based study","volume":"12","author":"Mahlknecht","year":"2025","journal-title":"Movement Disorders Clinical Practice"},{"key":"10.1016\/j.prdoa.2026.100440_b0310","doi-asserted-by":"crossref","unstructured":"S. Prasad, T. Nagaraj, S.G. Bhat, S.S. Purushotham, R. Taneja, M. Bhardwaj, D.K. Samartha, S.S. Aramugham, K.J. Kumar, P. Mailankody, R.R. Mahale, V.V. Holla, N. Kamble, R. Yadav, J. Saini, P.K. Pal, White matter alterations in tremor-dominant and postural instability and gait disturbance subtypes of Parkinson's disease, J. Neural Transmission (Vienna, Austria : 1996), 2025, 10.1007\/s00702-025-03001-2. Advance online publication. https:\/\/doi.org\/10.1007\/s00702-025-03001-2.","DOI":"10.2139\/ssrn.5189209"},{"issue":"1","key":"10.1016\/j.prdoa.2026.100440_b0315","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41531-022-00287-x","article-title":"The emerging postural instability phenotype in idiopathic Parkinson disease","volume":"8","author":"Skidmore","year":"2022","journal-title":"npj Parkinson's Dis."},{"issue":"2","key":"10.1016\/j.prdoa.2026.100440_b0320","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/mdc3.13107","article-title":"Neuroimaging detectable differences between parkinson's disease motor subtypes: a systematic review","volume":"8","author":"Boonstra","year":"2020","journal-title":"Movement Disorders Clinical Practice"},{"issue":"5","key":"10.1016\/j.prdoa.2026.100440_b0325","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson's disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"The Lancet. Neurology"},{"issue":"1","key":"10.1016\/j.prdoa.2026.100440_b0330","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41531-024-00768-1","article-title":"Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson's Disease","volume":"10","author":"Pedersen","year":"2024","journal-title":"npj Parkinson's Dis."},{"issue":"3","key":"10.1016\/j.prdoa.2026.100440_b0335","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mds.26913","article-title":"Biomarker-driven phenotyping in Parkinson's disease: a translational missing link in disease-modifying clinical trials","volume":"32","author":"Espay","year":"2017","journal-title":"Movement Disorders : Official J. Movement Disorder Soc."},{"issue":"2","key":"10.1016\/j.prdoa.2026.100440_b0340","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pharmthera.2010.07.006","article-title":"Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders","volume":"128","author":"Chiu","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.prdoa.2026.100440_b0345","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12868-015-0222-y","article-title":"Lithium protects dopaminergic cells from rotenone toxicity via autophagy enhancement","volume":"16","author":"Hou","year":"2015","journal-title":"BMC Neurosci."},{"issue":"1","key":"10.1016\/j.prdoa.2026.100440_b0350","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neulet.2012.03.055","article-title":"Lithium and oxidative stress lessons from the MPTP model of Parkinson's disease","volume":"516","author":"Arraf","year":"2012","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.prdoa.2026.100440_b0355","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11064-010-0368-z","article-title":"Lithium fails to protect dopaminergic neurons in the 6-OHDA model of Parkinson's disease","volume":"36","author":"Yong","year":"2011","journal-title":"Neurochem. Res."},{"issue":"2","key":"10.1016\/j.prdoa.2026.100440_b0360","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ana.410150224","article-title":"Lithium and parkinsonism","volume":"15","author":"Lang","year":"1984","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.prdoa.2026.100440_b0365","doi-asserted-by":"crossref","first-page":"107","DOI":"10.22551\/2023.39.1002.10252","article-title":"Lithium-induced parkinsonism associated with vocal cord paralysis: an atypical presentation","volume":"10","author":"Raia","year":"2023","journal-title":"Arch. Clin. Cases"},{"issue":"Suppl 1","key":"10.1016\/j.prdoa.2026.100440_b0370","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1192\/bjo.2022.358","article-title":"Lithium induced Parkinsonism: a case report","volume":"8","author":"Kavasoglu","year":"2022","journal-title":"Bjpsych Open"},{"issue":"12","key":"10.1016\/j.prdoa.2026.100440_b0375","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1017\/S1041610216001101","article-title":"A case of lithium-induced parkinsonism presenting with typical motor symptoms of Parkinson's disease in a bipolar patient","volume":"28","author":"Hermida","year":"2016","journal-title":"Int. Psychogeriatr."},{"issue":"4","key":"10.1016\/j.prdoa.2026.100440_b0380","first-page":"231","article-title":"Lithium intoxication-induced acute parkinsonism complicated with hyperparathyroidism and nephrogenic diabetes insipidus: report of a case","volume":"16","author":"Shen","year":"2007","journal-title":"Acta Neurol. Taiwan."},{"issue":"4","key":"10.1016\/j.prdoa.2026.100440_b0385","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jagp.2015.11.004","article-title":"Lithium use in older adults is associated with increased prescribing of parkinson medications","volume":"24","author":"Marras","year":"2016","journal-title":"Am. J. Geriatric Psychiatry : Official J. Am. Assoc. Geriatric Psychiatry"},{"issue":"4","key":"10.1016\/j.prdoa.2026.100440_b0390","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/0885066616651582","article-title":"Lithium poisoning","volume":"32","author":"Baird-Gunning","year":"2017","journal-title":"J. Intensive Care Med."},{"issue":"5","key":"10.1016\/j.prdoa.2026.100440_b0395","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1055\/a-2117-5200","article-title":"Lithium therapy in old age: recommendations from a Delphi survey","volume":"56","author":"Christl","year":"2023","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.prdoa.2026.100440_b0400","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1570159X13999150424113345","article-title":"Neuroleptic malignant syndrome: a review from a clinically oriented perspective","volume":"13","author":"Tse","year":"2015","journal-title":"Curr. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.prdoa.2026.100440_b0405","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5152\/alphapsychiatry.2024.231460","article-title":"The syndrome of irreversible lithium-effectuated neurotoxicity: a scoping review","volume":"25","author":"Konieczny","year":"2024","journal-title":"Alpha Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.prdoa.2026.100440_b0410","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jns.2008.10.010","article-title":"The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT): one-year follow-up of a single case","volume":"277","author":"Porto","year":"2009","journal-title":"J. Neurol. Sci."},{"issue":"14","key":"10.1016\/j.prdoa.2026.100440_b0195","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.1073\/pnas.95.14.8363","article-title":"Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex","volume":"95","author":"Dixon","year":"1998","journal-title":"PNAS"}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:16:00Z","timestamp":1783930560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112526000204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":82,"alternative-id":["S2590112526000204"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100440","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lithium as a disease-modifying therapy for Parkinson\u2019s disease: mechanisms, preclinical evidence, and clinical prospects","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100440"}}